Could new obesity drugs be funded by the state? Here’s who might qualify under Italy’s €250m plan

New hope for severe obesity? What the proposed £/€250m fund could mean for patients

Italian lawmakers have proposed an amendment to the 2027 budget that would allocate €250 million over three years to subsidise pharmacological treatments for people with severe obesity. If approved, this move would mark a significant policy shift: recognising that drug therapy can be an essential part of long‑term care for a chronic condition that affects millions. But who would qualify, what would be covered, and how might this change the lived experience of patients and families? Let’s unpack the proposal and what it might mean in practical terms.

What exactly does the proposal set out?

The amendment suggests a dedicated fund of €250 million split over three years: €50 million in 2027, and €100 million in each of 2028 and 2029. The money is intended to pilot a reimbursement model for pharmacological therapies aimed at people with severe obesity. In parallel, the amendment proposes a separate €6 million package to introduce screening for adolescents aged 13‑19, coordinated through schools and local health services — a prevention‑focused measure to catch weight issues early.

Who would be eligible for drug reimbursement?

The scheme would not be universal. It targets patients with severe clinical profiles. The criteria proposed are stringent and intended to focus limited resources on those at highest clinical risk:

  • Body Mass Index (BMI) ≥ 40 (class III obesity);
  • Presence of at least one obesity‑related comorbidity other than diabetes;
  • Considered eligible for bariatric surgery by clinical assessment;
  • Demonstrated insufficient response to lifestyle interventions and dietary measures.
  • In other words, the reimbursement would be part of a comprehensive, medically supervised pathway, not a first‑line, standalone option. A therapeutic plan would be defined and overseen by the national medicines agency.

    Which medications might be covered?

    The amendment does not list specific drugs. Today’s most discussed medicines for weight management include GLP‑1 receptor agonists and other newer agents that have demonstrated meaningful weight loss outcomes in trials. Inclusion in any reimbursement programme would depend on regulatory indications, cost‑effectiveness assessments and AIFA (Italy’s medicines agency) decisions. The pilot model could therefore help determine which agents deliver the best long‑term value for patients and the health system.

    Why this matters: equity and chronic disease care

    The Italian Society for Obesity (SIO) has welcomed the proposal. The central argument is one of equity: effective treatments exist but remain financially out of reach for many. Obesity is now recognised by Italian law as a chronic, progressive and relapsing disease — a stance that supports long‑term therapeutic approaches rather than one‑off interventions. Subsidising drugs for those with severe disease could reduce disparities in access tied to income or geography.

    The adolescent screening element

    Alongside treatment funding, the amendment proposes screening programmes for adolescents aged 13‑19, funded with €2 million per year over three years. This aims to identify young people at risk early and provide timely prevention and support, which is crucial — intervening during adolescence can alter lifelong trajectories. Any screening approach will need to account for growth and sex differences in BMI interpretation for under‑18s.

    Key benefits and potential risks

    Potential benefits:

  • Improved access to clinically effective therapies for people with the greatest need;
  • Reduced socioeconomic inequities in treatment access;
  • Structured care pathways that pair medication with dietary, psychological and surgical options when needed;
  • Early identification and prevention among adolescents, possibly reducing future disease burden.
  • Potential concerns and challenges:

  • High ongoing costs if patients require long‑term therapy to maintain weight loss;
  • Risk of over‑medicalising obesity without parallel investment in prevention, social determinants and lifestyle support;
  • Unclear prioritisation rules — will socioeconomically vulnerable patients be prioritised, and if so how?
  • Need for robust post‑market surveillance to understand long‑term benefits and harms.
  • What would access look like in practice?

    According to the proposed framework, access would require a clinical evaluation and a formal therapeutic plan from AIFA. That means patients would typically be assessed in specialised centres, have documentation of prior lifestyle interventions, and meet the comorbidity and BMI thresholds. The pilot nature of the programme suggests that selection and monitoring protocols would be refined over time.

    How might this affect patients and families?

    For someone with BMI ≥ 40 and related health problems, subsidised medication could be life‑changing: improved mobility, reduced risk of heart disease, better control of obesity‑related conditions and enhanced quality of life. Families often shoulder a heavy emotional and financial burden; public funding for treatment could ease that strain significantly.

    Questions still unanswered

  • Which drugs will be included, and on what clinical indications?
  • Will the scheme prioritise based on clinical need alone, or factor in socioeconomic vulnerability?
  • How will continuity of care be ensured if treatments must be continued long‑term?
  • What measures will be in place to integrate pharmacotherapy with dietetic, exercise and psychological support?
  • What to watch for next

    The amendment must pass through parliamentary debate and be finalised in the budget law. If adopted, subsequent work will be needed to define the lists of eligible medicines, the clinical pathway, monitoring indicators and the operational details of adolescent screening. Professional bodies, patient groups and clinicians will all play a role in shaping the final implementation.

    Practical tips for readers

  • If you or a family member have severe obesity, discuss current treatment options with your clinician — pathways exist even today, though access may be limited;
  • stay informed about the legislative process if you could be affected, as details will determine eligibility and access;
  • for parents, engage with local school health services to learn about planned screening and prevention initiatives;
  • remember that any medication works best as part of a multidisciplinary plan, including nutrition, movement and psychological support.
  • Exit mobile version